FDA Clarifies Evidence Standards for Digital Tools Used in Remote Monitoring and Preventive Health

FDA Clarifies Evidence Standards for Digital Tools Used in Remote Monitoring and Preventive Health

The U.S. Food and Drug Administration has restated its regulatory framework for digital health technologies used in remote monitoring and preventive health. The agency applies enforcement discretion to low-risk general wellness products that do not make claims related to the diagnosis, cure, mitigation, prevention, or treatment of specific diseases [1]. This position, first articulated in 2016 guidance and supported by the Digital Health Center of Excellence, aligns with exclusions established under the 21st Century Cures Act [2][3].

The clarification delineates the boundary between unregulated wellness tools and regulated medical devices. It addresses developer uncertainty regarding apps for fitness tracking, stress management, healthy eating, and similar functions while affirming that oversight is triggered when products cross into higher-risk territory.

FDA Policy on Low-Risk General Wellness Products

The FDA does not regulate products intended to promote general wellness that present low risk to users and do not make disease-related claims [1]. This policy, issued July 29, 2016, applies to certain digital tools used for remote monitoring and preventive health when their intended uses remain within general wellness parameters.

Risk-Based Regulatory Approach

Oversight is risk-based; technologies making claims to diagnose or treat diseases require FDA review [1]. The agency evaluates specific product claims on a case-by-case basis to determine whether a product meets the statutory definition of a device.

Role of the Digital Health Center of Excellence

The Digital Health Center of Excellence promotes innovation and regulatory clarity for digital health technologies including those used for prevention and wellness [2]. Its mission, referenced in agency materials dated September 1, 2022, supports consistent application of the general wellness policy across remote monitoring and preventive health tools.

Interaction with the 21st Century Cures Act

The 21st Century Cures Act established statutory exclusions for certain digital health and wellness technologies from the device definition [3]. This legislation provides the foundational legal distinction that determines when FDA enforcement discretion applies to low-risk preventive tools versus when premarket review is required.

What this means

The framework distinguishes general wellness claims from disease-specific prevention or treatment claims, resulting in enforcement discretion for many consumer-facing digital tools focused on diet, exercise, sleep, and stress management. Higher-risk products that cross the statutory device threshold remain subject to standard regulatory requirements. The approach reflects a consistent risk-based standard that has been in place since the 2016 guidance and Cures Act implementation.

Limitations

The guidance is non-binding and does not address software as a medical device (SaMD) in clinical contexts, international alignment (e.g., EMA), or rapidly evolving AI/ML technologies; specific product claims must still be evaluated case-by-case.